NASDAQ:GMDA - Gamida Cell Stock Price, Forecast & News

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Gamida Cell Ltd (NASDAQ:GMDA) issued its earnings results on Wednesday, November, 13th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. View Gamida Cell's Earnings History.

Gamida Cell is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Gamida Cell.

3 brokers have issued twelve-month price objectives for Gamida Cell's shares. Their forecasts range from $16.00 to $19.00. On average, they expect Gamida Cell's share price to reach $17.67 in the next year. This suggests a possible upside of 280.7% from the stock's current price. View Analyst Price Targets for Gamida Cell.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gamida Cell.

Media headlines about GMDA stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Gamida Cell earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Gamida Cell.

Gamida Cell saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 1,200 shares, a drop of 84.0% from the December 15th total of 7,500 shares. Based on an average daily trading volume, of 36,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are sold short. View Gamida Cell's Current Options Chain.

Some companies that are related to Gamida Cell include BioCryst Pharmaceuticals (BCRX), Adaptimmune Therapeutics (ADAP), Verona Pharma (TARA), Cabaletta Bio (CABA), Gritstone Oncology (GRTS), PDL BioPharma (PDLI), Harpoon Therapeutics (HARP), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), Tcr2 Therapeutics (TCRR), Compugen (CGEN), Scholar Rock (SRRK), Novavax (NVAX), CASI Pharmaceuticals (CASI) and Sutro Biopharma (STRO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Palatin Technologies (PTN), Cisco Systems (CSCO), LYFT (LYFT), Outlook Therapeutics (OTLK), Ovid Therapeutics (OVID), People's United Financial (PBCT), PhaseBio Pharmaceuticals (PHAS), Spring Bank Pharmaceuticals (SBPH), Sorrento Therapeutics (SRNE) and ONEOK (OKE).

(GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GMDA stock can currently be purchased for approximately $4.64.

Gamida Cell has a market capitalization of $112.38 million. The company earns $-52,930,000.00 in net income (profit) each year or ($10.53) on an earnings per share basis. Gamida Cell employs 70 workers across the globe.View Additional Information About Gamida Cell.

The official website for Gamida Cell is http://www.gamida-cell.com/.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]